Loading…
Bright Minds Biosciences Inc. is projected to rise to $93.34 by 2027, a +20% move from its current price of $77.84. DRUG is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $74.94 | $77.89 | $80.96 | +0.07% |
| Jul 13 | $73.80 | $77.94 | $82.32 | +0.13% |
| Jul 14 | $72.95 | $78.00 | $83.39 | +0.20% |
| Jul 15 | $72.25 | $78.05 | $84.32 | +0.27% |
| Jul 16 | $71.64 | $78.10 | $85.14 | +0.33% |
| Jul 17 | $71.10 | $78.15 | $85.91 | +0.40% |
| Jul 18 | $70.61 | $78.21 | $86.62 | +0.47% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $70.61 | $78.21 | $86.62 | +0.47% |
| Week 2 | $68.00 | $78.57 | $90.79 | +0.94% |
| Week 3 | $66.14 | $78.94 | $94.22 | +1.41% |
| Week 4 | $64.65 | $79.31 | $97.29 | +1.89% |
| Week 5 | $63.41 | $79.68 | $100.14 | +2.37% |
| Week 6 | $62.33 | $80.06 | $102.82 | +2.85% |
| Week 7 | $61.38 | $80.43 | $105.40 | +3.33% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bright Minds Biosciences Inc. is a biotechnology company that develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States.
Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study.
The company was founded in 2017 and is headquartered in New York, New York.
Current price: $78.20. Market cap: $767.3M. It ranks 2749.
Forecast path shows upside with the average price rising across years, including 2026 $78.20, 2027 $93.22, 2028 $103.68, 2029 $118.77, 2030 $162.06, 2040 $389.10, and 2050 $1,048.72.
ROI trajectory across years includes 2026 0, 2027 19.2, 2028 32.6, 2029 51.9, 2030 107.2, 2031 147.4, 2032 166.3, 2033 190.2, 2034 189.8, 2035 217.9, 2040 397.6, and 2050 1241.1.
A major floor 42.0% below — a decisive break under it would weaken the trend.
The nearest floor, 24.0% below — buyers have tended to step in here.
The nearest ceiling, 15.0% above — a clean break opens room to run.
A major ceiling 35.9% above — clearing it would confirm fresh momentum.
Key DRUG support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DRUG market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $71.44 | Buy | $73.31 | Buy |
| MA 10 | $69.65 | Buy | $70.55 | Buy |
| MA 20 | $65.83 | Buy | $69.48 | Buy |
| MA 50 | $74.89 | Buy | $72.68 | Buy |
| MA 100 | $77.70 | Buy | $74.54 | Buy |
| MA 200 | $74.36 | Buy | $69.92 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 61.75 | Neutral |
| Stoch RSI (14) | 97.55 | Sell |
| CCI (20) | 201.10 | Buy |
| Williams %R (14) | -2.45 | Info |
| MACD (12,26,9) | 2.02 | Buy |
| ROC (12) | 19.51 | Buy |
| Bollinger %B (20,2) | 1.07 | Sell |
| Stochastic %K (14) | 97.55 | Sell |
| TRIX (15) | -0.47 | Sell |
| Awesome (5,34) | 0.72 | Buy |
| Ultimate (7,14,28) | 65.86 | Neutral |
| Momentum (10) | 14.20 | Buy |
| Aroon Osc (25) | 64.00 | Buy |
| Hull MA (9) | 75.22 | Buy |
| ADX (14) | 19.59 | Neutral |
| ATR (14) | 2.54 | Info |
Near-term technical picture: BULLISH.
RSI14 is 60, with SMA50 at $75.11 and SMA200 at $74.22. Support is at $59.17 and resistance at $89.49. The 30-day range runs from $60.15 to $101.66. Annualized volatility is 80%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $59.17 | $77.84 | $115.40 | 0% | Neutral | |
| $71.44 | $93.34 | $130.58 | +20% | Neutral | |
| $76.16 | $103.69 | $152.40 | +33% | Bullish | |
| $84.57 | $119.21 | $182.02 | +53% | Bullish | |
| $111.57 | $162.21 | $255.70 | +108% | Bullish | |
| $129.04 | $193.02 | $312.80 | +148% | Bullish | |
| $135.74 | $208.56 | $346.39 | +168% | Bullish | |
| $144.44 | $227.62 | $386.54 | +192% | Bullish | |
| $141.04 | $227.74 | $394.66 | +193% | Bullish | |
| $151.81 | $250.95 | $443.12 | +222% | Bullish | |
| $212.88 | $392.50 | $749.22 | +404% | Bullish | |
| $474.52 | $1,054.49 | $2,249.93 | +12.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $59.17 | $77.84 | $94.67 | +0.00% |
| August 2026 | $68.89 | $82.25 | $101.50 | +5.67% |
| September 2026 | $68.61 | $82.73 | $103.67 | +0.59% |
| October 2026 | $67.38 | $81.96 | $104.03 | -0.94% |
| November 2026 | $69.95 | $85.71 | $109.97 | +4.58% |
| December 2026 | $72.20 | $89.06 | $115.40 | +3.91% |
Click any year to see its month-by-month DRUG forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect DRUG to range from $59.17 to $115.40 through 2026. The $77.84 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The DRUG price prediction for 2027 points to an average of $93.34 (low $71.44, high $130.58) — a potential gain of +20% on today's $77.84. Price action looks broadly range-bound.
In 2028, DRUG is projected to trade between $76.16 and $152.40, averaging $103.69 — a potential gain of +33% from today's $77.84. That is up +11% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Bright Minds Biosciences Inc.'s 2029 outlook centres on $119.21, within a $84.57 to $182.02 range. That is up +15% on the projected 2028 average. That marks a +53% change versus current levels. Momentum favours further upside here.
By 2030, DRUG could reach as high as $255.70, with a base case around $162.21 and support toward $111.57 — roughly +108% from $77.84. Buyers look set to stay in control over this stretch.
Expect DRUG to range from $129.04 to $312.80 through 2031. The $193.02 average target implies a +148% move from current prices. That is up +19% on the projected 2030 average. Momentum favours further upside here.
The DRUG price prediction for 2032 points to an average of $208.56 (low $135.74, high $346.39) — a potential gain of +168% on today's $77.84. Buyers look set to stay in control over this stretch.
In 2033, DRUG is projected to trade between $144.44 and $386.54, averaging $227.62 — a potential gain of +192% from today's $77.84. That is up +9% on the projected 2032 average. Momentum favours further upside here.
Bright Minds Biosciences Inc.'s 2034 outlook centres on $227.74, within a $141.04 to $394.66 range. That is up 0% on the projected 2033 average. That marks a +193% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, DRUG could reach as high as $443.12, with a base case around $250.95 and support toward $151.81 — roughly +222% from $77.84. Momentum favours further upside here.
Expect DRUG to range from $212.88 to $749.22 through 2040. The $392.50 average target implies a +404% move from current prices. That is up +56% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The DRUG price prediction for 2050 points to an average of $1,054.49 (low $474.52, high $2,249.93) — a potential gain of +12.5x on today's $77.84. Momentum favours further upside here.
Investing $1,000 in DRUG today (≈ 12.846865 DRUG) could be worth
$13,546.83
+$12,546.83 (+1255%) by 2050 · US Dollar
Based on the average projected DRUG price of $1,054.49 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DRUGwould be worth at today's price.
$1,000 invested in DRUG on Jul 10, 2025 (≈ 38.565368 DRUG) would be worth
$3,001.93
+$2,001.93 (+200.2%) today · 3.00× · US Dollar
Based on a DRUG entry price of $25.93 vs. today's $77.84.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $67.6 | $1,151.48 | +15.1% |
| 1 month ago | $61.56 | $1,264.46 | +26.4% |
| 3 months ago | $83.55 | $931.66 | -6.8% |
| 6 months ago | $88.67 | $877.86 | -12.2% |
| 1 year ago | $25.93 | $3,001.93 | +200.2% |
| All time (5.0y) ago | $22.75 | $3,421.54 | +242.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DRUG forecast.
Our base-case forecast reaches $160.00 around 2030.
Implied market cap at $160.00: $1.57B
The multi-year forecast shows bullish momentum into the late 2020s and beyond.
In 2030 the forecasted average price is $162.06 with a min of $110.55 and a max of $257.55, and a forecast ROI of 107.2.
In 2040 the forecasted average price is $389.10 with a min of $207.12 and a max of $751.70, and a forecast ROI of 397.6.
In 2050 the forecasted average price is $1,048.72 with a min of $471.92 and a max of $2,269.01, and a forecast ROI of 1241.1. Sentiment remains BULLISH in the later years. These figures are estimates and subject to change based on clinical outcomes, regulatory conditions, and market dynamics.
Tap a question to reveal the answer.
2030: min $110.55, avg $162.06, max $257.55; ROI 107.2; sentiment BULLISH.
The forecast shows upside through 2030–2050, with 2030 average $162.06, 2040 average $389.10, and 2050 average $1,048.72; ROI values rise to 107.2% by 2030 and 1241.1% by 2050; sentiment is BULLISH in later years.
Yes. The 2050 forecast lists an average of $1,048.72 and a max of $2,269.01.
Current price is $78.20.
30-day range is $60.15 to $101.66. RSI14 is 60. SMA50 is $75.11. SMA200 is $74.22. Support is $59.17 and resistance is $89.49. Sentiment is BULLISH.
Bright Minds Biosciences Inc. Community Discussion
0Share your Bright Minds Biosciences Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.